2020年度肺癌免疫治疗年终盘点

Inventory of immunotherapy for lung cancer in 2020

免疫检查点抑制剂因其显著的抗肿瘤活性,深刻改变了晚期一线非小细胞肺癌的治疗模式。KEYNOTE-024研究免疫单药组31.9%的5年生存率数据展示了免疫单药的生存“新高度”。免疫单药(KEYNOTE-024/042研究、EMPOWER Lung1研究)、免疫联合抗血管生成(WJOG@Be研究)以及免疫联合免疫(CheckMate-227研究)多种去化疗模式研究数据的公布预示着去化疗“新时代”的来临。在双免基础上的短程化疗+双免的“新方案”,IMpower-150研究探索性分析揭示了表皮生长因子受体阳性患者可能从免疫治疗中获益的“新希望”,众多国产程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂的加入构建了晚期一线非小细胞肺癌免疫联合化疗治疗的新格局。新联合、新靶点的研究正蓄势待发,期待开启免疫时代的新篇章。

Immune checkpoint inhibitors(ICIs)have profoundly changed the first-line treatment paradigm for advanced nonsmall cell lung cancer due to their significant antitumor activity.The 5-year survival data of 31.9%in the immune monotherapy group of the KEYNOTE-024 study demonstrates a"new level"of survival for immune monotherapy.The publication of data on multiple chemo-free modalities heralds a"new era"of chemo-free.In addition,a"new regimen"of short course chemotherapy plus dual immunotherapy based on dual immunotherapy has emerged.An exploratory analysis of IMpower-150 reveals"new hope"that epidermal growth factor receptor-positive patients may benefit from immunotherapy.The addition of many domestic programmed death-1/programmed death ligand-1 inhibitors has constructed the"new landscape"of immune combination chemotherapy treatment for advanced non-small cell lung cancer.New combinations and new targets are waiting to be researched,and we look forward to opening a new chapter in the immune era.